Literature DB >> 11276100

Proton MR spectroscopy in clinical routine.

I M Burtscher1, S Holtås.   

Abstract

In vivo magnetic resonance spectroscopy (MRS) addresses metabolic pathways and their steady states in different tissue types. The brain has by tradition, and due to technical limitations in other organs, been one of the tissues most studied by MRS, and both 1H- and 31P-MRS have been used. Although 31P-MRS is outstanding for the evaluation of sources of metabolic energy in the brain, 1H-MRS has become the major clinically applied method in neurospectroscopy, as it provides information on markers of neuronal function, myelin, cell membranes, and metabolic active compounds. Furthermore, MR sensitivity is much greater for protons than it is for phosphorus and 1H-MRS, therefore allowing better spatial resolution. This review focuses on neurospectroscopy and diagnostic insights into diverse neurological problems provided by 1H-MRS applied as a clinical tool.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11276100     DOI: 10.1002/jmri.1079

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  17 in total

1.  Hippocampus Glutamate and N-Acetyl Aspartate Markers of Excitotoxic Neuronal Compromise in Posttraumatic Stress Disorder.

Authors:  Isabelle M Rosso; David J Crowley; Marisa M Silveri; Scott L Rauch; J Eric Jensen
Journal:  Neuropsychopharmacology       Date:  2017-02-13       Impact factor: 7.853

2.  Proton spectroscopy and imaging at 3T in ataxia-telangiectasia.

Authors:  L I Wallis; P D Griffiths; S J Ritchie; C A J Romanowski; G Darwent; I D Wilkinson
Journal:  AJNR Am J Neuroradiol       Date:  2007-01       Impact factor: 3.825

Review 3.  Molecular imaging: current status and emerging strategies.

Authors:  M A Pysz; S S Gambhir; J K Willmann
Journal:  Clin Radiol       Date:  2010-07       Impact factor: 2.350

Review 4.  Molecular ultrasound assessment of tumor angiogenesis.

Authors:  Nirupama Deshpande; Marybeth A Pysz; Jürgen K Willmann
Journal:  Angiogenesis       Date:  2010-06-12       Impact factor: 9.596

5.  Spectroscopic imaging with prospective motion correction and retrospective phase correction.

Authors:  Thomas Lange; Julian Maclaren; Martin Buechert; Maxim Zaitsev
Journal:  Magn Reson Med       Date:  2011-08-29       Impact factor: 4.668

6.  Proton magnetic resonance spectroscopy and MRI reveal no evidence for brain mitochondrial dysfunction in children with autism spectrum disorder.

Authors:  Neva M Corrigan; Dennis W W Shaw; Todd L Richards; Annette M Estes; Seth D Friedman; Helen Petropoulos; Alan A Artru; Stephen R Dager
Journal:  J Autism Dev Disord       Date:  2012-01

Review 7.  [Magnetic resonance spectroscopy in schizophrenia. Possibilities and limitations].

Authors:  T Wobrock; H Scherk; P Falkai
Journal:  Radiologe       Date:  2005-02       Impact factor: 0.635

8.  Proton MR spectroscopy in the evaluation of cerebral metabolism in patients with fibromyalgia: comparison with healthy controls and correlation with symptom severity.

Authors:  M Petrou; R E Harris; B R Foerster; S A McLean; A Sen; D J Clauw; P C Sundgren
Journal:  AJNR Am J Neuroradiol       Date:  2008-03-13       Impact factor: 3.825

9.  SNAP-25 genotype influences NAA/Cho in left hippocampus.

Authors:  Harald Scherk; Martin Backens; Peter Zill; Thomas Schneider-Axmann; Thomas Wobrock; Juliana Usher; Wolfgang Reith; Peter Falkai; Hans-Jürgen Möller; Brigitta Bondy; Oliver Gruber
Journal:  J Neural Transm (Vienna)       Date:  2008-08-23       Impact factor: 3.575

10.  Altered neurochemical ingredient of hippocampus in patients with bipolar depression.

Authors:  Murad Atmaca; Hanefi Yildirim
Journal:  Depress Res Treat       Date:  2012-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.